目次

Table of Content

1. Introduction To Peptide Cancer Vaccines
1.1 Overview and Historical Context
1.2 Peptide Based Immunotherapy In Oncology

2. Need For Peptide Cancer Vaccines
2.1 Why Peptides Are More Desirable In Cancer Immunotherapy
2.2 Peptide Vaccines vs. Traditional Cancer Vaccines
2.3 Gaps Addressed By Peptide Vaccines

3. Peptide Cancer Vaccines Mechanism Of Action

4. Classification Of Peptide Cancer Vaccines
4.1 Based On Source Of Peptides
4.2 Based on Peptide Length
4.3 Based on Epitope Specificity

5. Peptide Cancer Vaccines Development and Clinical Trends By Indication
5.1 Brain Cancer
5.2 Breast Cancer
5.3 Lung Cancer
5.4 Skin Cancers
5.5 Gastrointestinal Cancers
5.6 Gynecologic Cancers

6. Global Peptide Cancer Vaccine Market Overview
6.1 Current Market Landscape
6.2 Future Outlook and Innovation Opportunities

7. Global Peptide Cancer Vaccine Market Development Trends By Region
7.1 US
7.2 Europe
7.3 China
7.4 Japan
7.5 South Korea

8. Global Peptide Cancer Vaccine Pipeline Overview
8.1 By Country
8.2 By Company
8.3 By Indication
8.4 By Phase

9. Global Peptide Cancer Vaccine Clinical Trials Insight By Company, Country, Phase and Indication
9.1 Preclinical
9.2 Phase-I
9.3 Phase-I/II
9.4 Phase-II
9.5 Phase-III

10. Global Peptide Cancer Vaccine Market Dynamics
10.1 Key Drivers and Opportunities
10.2 Market Challenges and Limitations

11. Technology Platforms For Peptide Cancer Vaccine Development By Companies

12. Competitive Landscape
12.1 3D Medicines
12.2 BrightPath Biotherapeutics
12.3 Circio Holding
12.4 Cecava
12.5 DxandVx
12.6 Elicio
12.7 Evaxion
12.8 GemVax and KAEL
12.9 IO Biotech
12.10 ISA Pharmaceuticals
12.11 OncoTherapy Science
12.12 OSE Immunotherapeutics
12.13 Nouscom
12.14 Nykode Therapeutics
12.15 Scancell
12.16 SELLAS Life Sciences
12.17 Seqker Biosciences
12.18 Shionogi
12.19 Vaxon Biotech
12.20 Zelluna

List of Figures
Figure 1-1: Peptide Cancer Vaccine Development - Key Milestones
Figure 1-2: Personalized Peptide Vaccines Based On Neoantigens
Figure 1-3: Peptide-Based Cancer Immunotherapy Mechanism
Figure 1-4: Dual Pathway Activation Via Peptides
Figure 1-5: Peptide Delivery Technologies
Figure 1-6: Peptide Combination Therapies
Figure 1-7: Peptide Immunotherapy - Challenges vs Solutions
Figure 2-1: Benefits of Peptides in Immunotherapy
Figure 2-2: Tumor Types and Peptide Targets
Figure 2-3: Multifunctional Peptides In Immunotherapy
Figure 2-4: Peptide-Based Immunotherapies In Global Health
Figure 2-5: Antigen Loss and Immune Escape vs Multi-Epitope Vaccination
Figure 3 1: Peptide Cancer Vaccines - Mechanism Of Action
Figure 4-1: Tumor-Associated Antigen Sources
Figure 4-2: Neoantigen Generation Sources
Figure 4-3: Tumor-Associated Antigen vs. Tumor-Specific Antigen-Derived Peptide Vaccines - Microenvironment Impact
Figure 4-4: Short Peptides - Pros and Cons
Figure 4-5: Long Peptides - Pros and Cons
Figure 4-6: Short and Long Peptide Vaccines - Antigen Processing and Presentation Pathways
Figure 4-7: CD8? T Cell Activation Functional Outcomes
Figure 4-8: CD4? T Cell Activation Functional Outcomes
Figure 4-9: MHC Class I and II - Antigen Processing Pathways
Figure 5-1: SURVIVE Phase II (NCT05163080) Study - Initiation and Estimated Completion Year
Figure 5-2: NCI-2015-00694 Phase II (NCT02455557) Study - Initiation and Estimated Completion Year
Figure 5-3: CONNECT1906 Phase II (NCT05096481) Study - Initiation and Estimated Completion Year
Figure 5-4: PRO13110086 Phase II (NCT02358187) Study - Initiation and Estimated Completion Year
Figure 5-5: PRO12050422 Phase I (NCT01795313) Study - Initiation and Estimated Completion Year
Figure 5-6: FLAMINGO-01 Phase III (NCT05232916) Study - Initiation and Estimated Completion Year
Figure 5-7: Pro00104868 Phase I (NCT04270149) Study - Initiation and Estimated Completion Year
Figure 5-8: CTO-IUSCCC-09138 Phase I (NCT06414733) Study - Initiation and Estimated Completion Year
Figure 5-9: 16-132 Phase I (NCT02826434) Study - Initiation and Estimated Completion Year
Figure 5-10: NCI-2016-01878 Phase II (NCT03012100) Study - Initiation and Estimated Completion Year
Figure 5-11: ARTEMIA Phase III (NCT06472245) Study - Initiation and Estimated Completion Year
Figure 5-12: PNeoVCA Phase I/II (NCT05269381) Study - Initiation and Estimated Completion Year
Figure 5-13: J23120 Phase I/II (NCT05950139) Study - Initiation and Estimated Completion Year
Figure 5-14: AMPLIFY-201 Phase I (NCT04853017) Study - Initiation and Estimated Completion Year
Figure 5-15: 18-279 Phase I (NCT03929029) Study - Initiation and Estimated Completion Year
Figure 5-16: KEYNOTE-D18 Phase III (NCT05155254) Study - Initiation and Estimated Completion Year
Figure 5-17: AMPLIFY-7P Phase I/II (NCT05726864) Study - Initiation and Estimated Completion Year
Figure 5-18: OBERTO-301 Phase II (NCT05243862) Study - Initiation and Estimated Completion Year
Figure 5-19: TEDOPAM Phase II (NCT03806309) Study - Initiation and Estimated Completion Year
Figure 5-20: GO-010 Phase II/III (NCT05141721) Study - Initiation and Estimated Completion Year
Figure 5-21: AMC-099 Phase III (NCT03284866) Study - Initiation and Estimated Completion Year
Figure 5-22: SAHoWMU-CR2024-07-107 Phase II/III (NCT06341907) Study - Initiation and Estimated Completion Year
Figure 5-23: GINECO-OV244b Phase II (NCT04713514) Study - Initiation and Estimated Completion Year
Figure 6-1: Global Cancer Peptide Vaccine Market - Future Opportunities
Figure 8-1: Global - Peptide Cancer Vaccine in Clinical Pipeline by Country, 2025 Till 2030
Figure 8-2: Global - Peptide Cancer Vaccine in Clinical Pipeline by Company, 2025 Till 2030
Figure 8-3: Global - Peptide Cancer Vaccine in Clinical Pipeline by Indication, 2025 Till 2030
Figure 8-4: Global - Peptide Cancer Vaccine in Clinical Pipeline by Phase, 2025 Till 2030
Figure 10-1: Global Cancer Peptide Vaccine Market - Market Drivers and Opportunities
Figure 10-2: Global Cancer Peptide Vaccine Market - Market Challenges and Limitations
Figure 11-1: Cecava - Personalized Neoepitope Peptide Vaccine Platform
Figure 11-2: IO Biotech - T-win
Figure 11-3: ISA Pharmaceuticals - SLP Technology

List of Tables
Table 2-1: Peptide Vaccines vs. Traditional Cancer Vaccines
Table 2-2: Gaps In Cancer Treatment Addressed By Peptide Vaccines
Table 4-1: Tumor-Associated Antigen vs. Tumor-Specific Antigen-Derived Peptide Vaccines
Table 4-2: Short vs Long Peptide Vaccines
Table 4-3: Short vs Long Peptide Vaccines - Ideal Candidate Use Scenarios
Table 4-4: MHC Class I vs MHC Class II Peptide Vaccines
Table 4-5: MHC-I and MHC-II Vaccines - Unique and Overlapping Features